News Ligand Pharmaceuticals Incorporated

Equities

LGND

US53220K5048

Real-time Estimate Cboe BZX Other stock markets 09:35:23 2023-10-03 am EDT			5-day change	1st Jan Change
58.87 ^USD	-0.52%		+0.53%	-11.42%

Sep. 27	Ligand Pharmaceuticals Completes Acquisition of Novan Assets	MT
Sep. 27	Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.	CI

Summary

Ligand Pharmaceuticals Completes Acquisition of Novan Assets	Sep. 27	MT
Ligand Acquires Assets of Novan, Inc. for $12.2 Million	Sep. 27	BU
Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.	Sep. 26	CI
Ligand Pharmaceuticals Incorporated Appoints Martine Zimmermann to its Board of Directors	Sep. 26	CI
Ligand Appoints Martine Zimmermann to its Board of Directors	Sep. 26	BU
LIGAND'S PARTNER JAZZ PHARMACEUTICALS RECEIVES EUROPEAN COMMISSION APPROVAL FOR ENRYLAZE FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOBLASTIC LYMPHOMA	Sep. 25	AQ
Jazz Pharmaceuticals Says Cancer Drug Enrylaze Granted Marketing Authorization in EU	Sep. 22	MT
LIGAND'S PARTNER TRAVERE THERAPEUTICS ANNOUNCES CONFIRMATORY DATA FROM THE PHASE 3 PROTECT STUDY OF FILSPARI DEMONSTRATING LONG-TERM KIDNEY FUNCTION PRESERVATION IN IGA NEPHROPATHY	Sep. 22	AQ
Ligand's Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma	Sep. 22	BU
Ligand's Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control	Sep. 21	BU
A Collaborative Scientific Team Led by Researchers At the Applied Biomedical Science Institute, Scripps Research, Kansas State University, University of Louisville, Omniab, Inc., and Ligand Pharmaceuticals Discovers and Validates Potential New Class of Therapeutic Agent Based on the Unique Antigen Binding Regions of Cow Antibodies	Sep. 20	CI
Ligand Pharmaceuticals Spins Out Pelican Technology, Updates 2023 Guidance	Sep. 18	MT
Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio	Sep. 18	BU
Primordial Genetics, Inc. acquired Pelican Technology Holdings, Inc. from Ligand Pharmaceuticals Incorporated.	Sep. 17	CI
Ligand Pharmaceuticals Incorporated : September Corporate Presentation	Sep. 06	PU
Ligand Pharmaceuticals Incorporated : October Corporate Presentation	Sep. 06	PU
LIGAND PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(4)	Sep. 04	AQ
Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)	Sep. 01	BU
Tranche Update on Ligand Pharmaceuticals Incorporated's Equity Buyback Plan announced on August 8, 2023.	Aug. 09	CI
Ligand Pharmaceuticals Q2 Adjusted Earnings Up, Revenue Down; Raises 2023 Adjusted EPS Outlook	Aug. 09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features

News Ligand Pharmaceuticals Incorporated

Equities

LGND

US53220K5048

Summary

Filters